Phenominer Database Results (23 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Average Type Value Units SEM SD Method Method Duration Post Insult Time Value Method Notes Clinical Measurement Notes Record ID Study ID
ACI/SegHsd both testes wet weight control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. testis mass male 900 days 12 2.81 g post excision weight measurement 0 0 65820 341
ACI/SegHsd prostate tumorous lesion number control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900 days 12 5.3 null ex vivo light microscopy 0 0 65822 341
ACI/SegHsd ventral prostate gland wet weight control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. ventral prostate mass male 900 days 12 0.32 g post excision weight measurement 0.0 0 65826 341
ACI/SegHsd prostate gland wet weight control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate mass male 900 days 12 1.54 g post excision weight measurement 0 0 65828 341
ACI/SegHsd body weight control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. body mass male 900 days 12 null 419.6 g body weighing method 0 method not specified, assumed to be digital scale 13301 341
ACI/SegHsd percentage of study population developing bilateral testis tumors during a period of time control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. testis integrity trait male 900 days 12 25.0 % ex vivo light microscopy 0.0 0 necropsy bilateral testis tumor incidence 67948 341
ACI/SegHsd area of ventral prostate occupied by tumorous lesions with solid structure to total ventral prostate area ratio control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900 days 12 1.09 % 0.38 1.31 ex vivo light microscopy with digital image analysis 0.0 0 109891 341
ACI/SegHsd percentage of study population developing ventral prostate tumorous lesions with a solid structure during a period of time control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900 days 12 92.0 % ex vivo light microscopy 0.0 0 109885 341
ACI/SegHsd area of individual prostate tumorous lesion control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900 days 12 1.78 mm2 ex vivo light microscopy with digital image analysis 0 0 65838 341
ACI/SegHsd percentage of study population developing subcutaneous tumors during a period of time control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. hypodermis integrity trait male 900 days 12 0.0 % necropsy 0.0 0 CMO:0003387 percentage of study population developing subcutaneous tumors during a period of time 106887 341
ACI/SegHsd percentage of study population developing unilateral renal agenesis during a period of time control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. kidney integrity trait male 900 days 12 24.0 % necropsy 0.0 0 106885 341
ACI/SegHsd percentage of study population developing ventral prostate tumorous lesions with round, irregular size nuclei during a period of time control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900 days 12 100.0 % ex vivo light microscopy 0.0 0 109957 341
ACI/SegHsd percentage of study population developing ventral prostate tumorous lesions during a period of time control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900 days 12 100.0 % ex vivo light microscopy 0 0 65825 341
ACI/SegHsd percentage of study population developing testis tumors during a period of time control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. testis integrity trait male 900 days 12 92.0 % ex vivo light microscopy 0.0 0 testis tumor incidence 65840 341
ACI/SegHsd spleen wet weight control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. spleen mass male 900 days 12 null 0.8 g post excision weight measurement 0 method not specified, assumed to be digital scale 13305 341
ACI/SegHsd area of ventral prostate occupied by tumorous lesions to total ventral prostate area ratio control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900 days 12 1.61 % ex vivo light microscopy with digital image analysis 0.0 0 67946 341
ACI/SegHsd area of individual ventral prostate tumorous lesion with a solid structure control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900 days 12 1.17 mm2 0.36 1.25 ex vivo light microscopy with digital image analysis 0.0 0 109889 341
ACI/SegHsd number of ventral prostate tumorous lesions with solid structure control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900 days 12 3.0 null 0.75 2.6 ex vivo light microscopy 0.0 0 109887 341
ACI/SegHsd number of ventral prostate tumorous lesions with round, irregular size nuclei control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900 days 12 5.1 null 0.69 2.4 ex vivo light microscopy 0.0 0 109959 341
ACI/SegHsd area of individual ventral prostate tumorous lesion with round, irregular size nuclei control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900 days 12 1.73 mm2 0.36 1.24 ex vivo light microscopy with digital image analysis 0.0 0 109961 341
ACI/SegHsd area of ventral prostate occupied by tumorous lesions with round, irregular size nuclei to total ventral prostate area ratio control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900 days 12 1.57 % 0.38 1.31 ex vivo light microscopy with digital image analysis 0.0 0 109963 341
ACI/SegHsd liver wet weight control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. liver mass male 900 days 12 null 11.3 g post excision weight measurement 0 method not specified, assumed to be digital scale 13303 341
ACI/SegHsd percentage of study population developing leukemia during a period of time control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. leukocyte integrity trait male 900 days 12 0.0 % ex vivo light microscopy 0 0 leukemia incidence 66143 341